Sentara Health Plans · Effective Nov 1, 2025Medium impact
Authorization Updates - Effective November 1, 2025
Sentara Health Plans' authorization updates effective November 1, 2025 archived the Apixaban (Eliquis) Drug Level policy (Medical 303), Corneal Procedures (Surgical 55) and Percutaneous Transluminal Coronary Lithotripsy for all lines of business, and archived Injectable Hormone Pellets (Medical 157) for Commercial and Medicaid. The same date archived the Substernal Implantable Cardioverter-Defibrillator (Surgical 130) and Thermal Intradiscal Procedures (Surgical 79) policies for Commercial and Medicaid, renamed the subcutaneous defibrillator policy Subcutaneous and Substernal Implantable Cardioverter-Defibrillator, and set authorization required (Y) for codes 28446 and 29891 and for J8597 (Commercial). Criteria were also updated for Commercial and Medicaid for compression stockings, leadless cardiac pacemakers, skin and tissue substitutes, and spinal and other pain management procedures.